Do analysts recommend MENS or FLNA?

Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 509.68%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cassava Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings & valuation, MENS or FLNA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is MENS or FLNA more profitable?

Jyong Biotech's return on equity of 0.00% beat Cassava Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Cassava Sciences N/A -58.78% -36.74%

Is UNCY or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Cassava Sciences N/A -58.78% -36.74%

Which has preferable earnings and valuation, AARD or FLNA?

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Cassava Sciences N/A N/A -$90.97M -$0.87 N/A

Is AARD or FLNA more profitable?

Cassava Sciences' return on equity of -58.78% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Cassava Sciences N/A -58.78% -36.74%

Cassava Sciences (FLNA) Competitors

$0.82 -0.01 (-0.99%)

As of 09/4/2026 04:00 PM Eastern

Compare

FLNA vs. LFCR, MENS, NRXP, UNCY, and AARD

Should you buy Cassava Sciences stock or one of its competitors? Cassava Sciences's main competitors and comparable companies include Lifecore Biomedical (LFCR), Jyong Biotech (MENS), NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cassava Sciences compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

In the previous week, Lifecore Biomedical had 6 more articles in the media than Cassava Sciences. MarketBeat recorded 6 mentions for Lifecore Biomedical and 0 mentions for Cassava Sciences. Lifecore Biomedical's average media sentiment score of 0.67 beat Cassava Sciences' score of 0.00 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Positive
Cassava Sciences	Neutral

Cassava Sciences has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Cassava Sciences	N/A	-58.78%	-36.74%

Lifecore Biomedical has a beta of 1.08, meaning that its stock price is 8% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, meaning that its stock price is 169% less volatile than the broader market.

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by insiders. Comparatively, 4.6% of Cassava Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Lifecore Biomedical has higher revenue and earnings than Cassava Sciences. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.29	-$40.50M	-$1.07	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Lifecore Biomedical currently has a consensus target price of $6.50, indicating a potential upside of 47.73%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 509.68%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifecore Biomedical beats Cassava Sciences on 9 of the 13 factors compared between the two stocks.

How does Cassava Sciences compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, earnings, valuation, media sentiment, risk, analyst recommendations, profitability and institutional ownership.

Jyong Biotech has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, suggesting that its stock price is 169% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Cassava Sciences has a consensus price target of $5.00, suggesting a potential upside of 509.68%. Given Cassava Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Jyong Biotech had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for Jyong Biotech and 0 mentions for Cassava Sciences. Jyong Biotech's average media sentiment score of 0.00 equaled Cassava Sciences'average media sentiment score.

Company	Overall Sentiment
Jyong Biotech	Neutral
Cassava Sciences	Neutral

Jyong Biotech's return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Cassava Sciences	N/A	-58.78%	-36.74%

38.0% of Cassava Sciences shares are owned by institutional investors. 4.6% of Cassava Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Jyong Biotech and Cassava Sciences tied by winning 5 of the 10 factors compared between the two stocks.

How does Cassava Sciences compare to NRx Pharmaceuticals?

Cassava Sciences (NASDAQ:FLNA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, dividends and earnings.

NRx Pharmaceuticals has higher revenue and earnings than Cassava Sciences. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A
NRx Pharmaceuticals	$1.23M	122.86	-$28.62M	-$0.55	N/A

In the previous week, Cassava Sciences' average media sentiment score of 0.00 beat NRx Pharmaceuticals' score of -1.19 indicating that Cassava Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cassava Sciences	Neutral
NRx Pharmaceuticals	Negative

Cassava Sciences has a beta of -0.69, suggesting that its share price is 169% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, suggesting that its share price is 119% more volatile than the broader market.

Cassava Sciences has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Cassava Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cassava Sciences	N/A	-58.78%	-36.74%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are held by institutional investors. 4.6% of Cassava Sciences shares are held by company insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cassava Sciences presently has a consensus price target of $5.00, suggesting a potential upside of 509.68%. NRx Pharmaceuticals has a consensus price target of $34.50, suggesting a potential upside of 888.54%. Given NRx Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe NRx Pharmaceuticals is more favorable than Cassava Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Summary

NRx Pharmaceuticals beats Cassava Sciences on 9 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, Unicycive Therapeutics had 10 more articles in the media than Cassava Sciences. MarketBeat recorded 10 mentions for Unicycive Therapeutics and 0 mentions for Cassava Sciences. Unicycive Therapeutics' average media sentiment score of 0.13 beat Cassava Sciences' score of 0.00 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Neutral
Cassava Sciences	Neutral

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 38.0% of Cassava Sciences shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by insiders. Comparatively, 4.6% of Cassava Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Cassava Sciences' return on equity of -58.78% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Cassava Sciences	N/A	-58.78%	-36.74%

Unicycive Therapeutics currently has a consensus target price of $18.75, indicating a potential upside of 263.37%. Cassava Sciences has a consensus target price of $5.00, indicating a potential upside of 509.68%. Given Cassava Sciences' higher probable upside, analysts clearly believe Cassava Sciences is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Unicycive Therapeutics has a beta of 1.79, indicating that its share price is 79% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, indicating that its share price is 169% less volatile than the broader market.

Unicycive Therapeutics has higher revenue and earnings than Cassava Sciences. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	211.33	-$26.56M	-$1.75	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Summary

Unicycive Therapeutics beats Cassava Sciences on 9 of the 14 factors compared between the two stocks.

How does Cassava Sciences compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Cassava Sciences (NASDAQ:FLNA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Aardvark Therapeutics had 23 more articles in the media than Cassava Sciences. MarketBeat recorded 23 mentions for Aardvark Therapeutics and 0 mentions for Cassava Sciences. Aardvark Therapeutics' average media sentiment score of 0.02 beat Cassava Sciences' score of 0.00 indicating that Aardvark Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Cassava Sciences	Neutral

38.0% of Cassava Sciences shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by company insiders. Comparatively, 4.6% of Cassava Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Cassava Sciences' return on equity of -58.78% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Cassava Sciences	N/A	-58.78%	-36.74%

Aardvark Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 185.01%. Cassava Sciences has a consensus price target of $5.00, indicating a potential upside of 509.68%. Given Cassava Sciences' higher possible upside, analysts plainly believe Cassava Sciences is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Cassava Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Aardvark Therapeutics has a beta of 3.74, indicating that its stock price is 274% more volatile than the broader market. Comparatively, Cassava Sciences has a beta of -0.69, indicating that its stock price is 169% less volatile than the broader market.

Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Cassava Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Cassava Sciences	N/A	N/A	-$90.97M	-$0.87	N/A

Summary

Aardvark Therapeutics beats Cassava Sciences on 8 of the 14 factors compared between the two stocks.

Get Cassava Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FLNA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FLNA vs. The Competition

Export

Metric	Cassava Sciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.62M	$12.25B	$7.25B	$12.92B
Dividend Yield	N/A	2.58%	2.53%	9.14%
P/E Ratio	-0.94	792.20	273.54	25.43
Price / Sales	N/A	754.62	630.11	96.68
Price / Cash	N/A	90.26	77.08	52.44
Price / Book	0.62	12.47	12.85	6.17
Net Income	-$90.97M	$2.83B	$3.49B	$350.08M
7 Day Performance	-11.72%	4.03%	1.04%	-0.14%
1 Month Performance	-14.56%	6.29%	5.52%	1.02%
1 Year Performance	-62.03%	9.93%	24.39%	14.51%

Cassava Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FLNA Cassava Sciences	1.3571 of 5 stars	$0.82 -1.0%	$5.00 +509.7%	-61.9%	$39.62M	N/A	N/A	20
LFCR Lifecore Biomedical	2.0633 of 5 stars	$4.52 -0.6%	$6.50 +44.0%	-44.6%	$170.86M	$128.87M	N/A	690	News Coverage Positive News
MENS Jyong Biotech	N/A	$2.20 +0.7%	N/A	-95.7%	$166.88M	N/A	N/A	31	News Coverage Gap Up
NRXP NRx Pharmaceuticals	1.7261 of 5 stars	$3.51 -1.4%	$34.50 +882.9%	+32.7%	$151.85M	$1.23M	N/A	2
UNCY Unicycive Therapeutics	2.7197 of 5 stars	$5.37 -4.6%	$18.75 +249.2%	+19.4%	$149.42M	$680K	N/A	9	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FLNA) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cassava Sciences (FLNA) Competitors

FLNA vs. LFCR, MENS, NRXP, UNCY, and AARD

How does Cassava Sciences compare to Lifecore Biomedical?

Summary

How does Cassava Sciences compare to Jyong Biotech?

Summary

How does Cassava Sciences compare to NRx Pharmaceuticals?

Summary

How does Cassava Sciences compare to Unicycive Therapeutics?

Summary

How does Cassava Sciences compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cassava Sciences (FLNA) Competitors

FLNA vs. LFCR, MENS, NRXP, UNCY, and AARD

How does Cassava Sciences compare to Lifecore Biomedical?

Does the media refer more to LFCR or FLNA?

Is LFCR or FLNA more profitable?

Which has more risk and volatility, LFCR or FLNA?

Do insiders & institutionals have more ownership in LFCR or FLNA?

Which has better earnings & valuation, LFCR or FLNA?

Do analysts recommend LFCR or FLNA?

Summary

How does Cassava Sciences compare to Jyong Biotech?

Which has more risk and volatility, MENS or FLNA?

Which has higher earnings & valuation, MENS or FLNA?

Do analysts recommend MENS or FLNA?

Does the media refer more to MENS or FLNA?

Is MENS or FLNA more profitable?

Do insiders & institutionals hold more shares of MENS or FLNA?

Summary

How does Cassava Sciences compare to NRx Pharmaceuticals?

Which has better valuation & earnings, FLNA or NRXP?

Does the media prefer FLNA or NRXP?

Which has more volatility and risk, FLNA or NRXP?

Is FLNA or NRXP more profitable?

Do institutionals & insiders hold more shares of FLNA or NRXP?

Do analysts rate FLNA or NRXP?

Summary

How does Cassava Sciences compare to Unicycive Therapeutics?

Does the media refer more to UNCY or FLNA?

Do institutionals & insiders believe in UNCY or FLNA?

Is UNCY or FLNA more profitable?

Do analysts recommend UNCY or FLNA?

Which has more volatility and risk, UNCY or FLNA?

Which has higher valuation & earnings, UNCY or FLNA?

Summary

How does Cassava Sciences compare to Aardvark Therapeutics?

Does the media refer more to AARD or FLNA?

Do institutionals and insiders believe in AARD or FLNA?

Is AARD or FLNA more profitable?

Do analysts recommend AARD or FLNA?

Which has more risk & volatility, AARD or FLNA?

Which has preferable earnings and valuation, AARD or FLNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FLNA vs. The Competition

Cassava Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools